Ipodate sodium (sodium iopodate) is an iodine-containing radiopaque contrast media used for X-rays. The drug is given orally and the resulting contrast allows for easy resolution of the bile duct and gall bladder.

Ipodate sodium
Clinical data
Trade namesOragrafin
Routes of
administration
oral, Intravenous
ATC code
Identifiers
  • sodium 3-(3-{[(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.013.587 Edit this at Wikidata
Chemical and physical data
FormulaC12H12I3N2NaO2
Molar mass619.943 g·mol−1
3D model (JSmol)
Melting point168–169 °C (334–336 °F)
  • CN(C)/C=N/c1c(cc(c(c1I)CCC(=O)[O-])I)I.[Na+]
  • InChI=1S/C12H13I3N2O2.Na/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h5-6H,3-4H2,1-2H3,(H,18,19);/q;+1/p-1/b16-6+;
  • Key:ZFHZUGUCWJVEQC-FPUQOWELSA-M

Other uses

edit

Although not FDA approved, ipodate sodium has been used to treat Graves' disease and thyroid storm, an extreme form of hyperthyroidism.

Graves' disease

edit

Long-term treatment of Graves' disease with ipodate sodium (500 mg, daily) given by mouth reduced levels of T3 and T4 in the patients.[1] This was done with minimal side effects, indicating possible clinical usefulness. Iodine uptake was also noted to return to normal within seven days, indicating control with ipodate with rapid follow up treatment with 131I is feasible.

Thyroid storm

edit

In emergency situations, ipodate can be administered for thyroid storm. As the ipodate is metabolized, it releases iodine into circulation, helping bring the T3 and T4 levels back down. Ipodate also inhibits the conversion of T4 to T3 (which is more potent). It is not considered a first-line approach, as potassium iodide and beta blockers have less potential for side-effects. Ipodate sodium lacks FDA approval for this use.

References

edit
  1. ^ Shen DC, Wu SY, Chopra IJ, Huang HW, Shian LR, Bian TY, et al. (October 1985). "Long term treatment of Graves' hyperthyroidism with sodium ipodate". The Journal of Clinical Endocrinology and Metabolism. 61 (4): 723–7. doi:10.1210/jcem-61-4-723. PMID 3928675. Archived from the original on 2008-07-25. Retrieved 2008-04-14.